Goldman Sachs
KRRO icon

Goldman Sachs’s Korro Bio KRRO Stock Holding History

Goldman Sachs’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.54M Buy
116,983
+66,442
+131% +$826K ﹤0.01% 4879
2026
Q1 		$572K Sell
50,541
-1,409
-3% -$15.5K ﹤0.01% 5519
2025
Q4 		$416K Buy
51,950
+36,269
+231% +$848K ﹤0.01% 5705
2025
Q3 		$751K Buy
+15,681
New +$348K ﹤0.01% 5239
2025
Q2 		– Sell
-20,944
Closed -$365K – 6270
2025
Q1 		$365K Sell
20,944
-2,357
-10% -$69.9K ﹤0.01% 5369
2024
Q4 		$887K Buy
23,301
+10,487
+82% +$539K ﹤0.01% 4901
2024
Q3 		$428K Buy
12,814
+3,823
+43% +$161K ﹤0.01% 5130
2024
Q2 		$305K Sell
8,991
-36,180
-80% -$2M ﹤0.01% 5099
2024
Q1 		$4.07M Buy
+45,171
New +$2.47M ﹤0.01% 3289
2023
Q4 		– Sell
-4,242
Closed -$78.5K – 5734
2023
Q3 		$78.5K Buy
+4,242
New +$106K ﹤0.01% 5226
2023
Q1 		– Sell
-859
Closed -$165K – 6097
2022
Q4 		$165K Sell
859
-260
-23% -$26.8K ﹤0.01% 5365
2022
Q3 		$100K Sell
1,119
-402
-26% -$40.8K ﹤0.01% 5683
2022
Q2 		$114K Sell
1,521
-1,749
-53% -$118K ﹤0.01% 5821
2022
Q1 		$346K Buy
3,270
+482
+17% +$92.1K ﹤0.01% 5587
2021
Q4 		$715K Buy
2,788
+74
+3% +$22.5K ﹤0.01% 5107
2021
Q3 		$958K Buy
2,714
+1,033
+61% +$407K ﹤0.01% 4781
2021
Q2 		$837K Buy
1,681
+1,159
+222% +$566K ﹤0.01% 4889
2021
Q1 		$248K Sell
522
-9
-2% -$17.5K ﹤0.01% 5532
2020
Q4 		$937K Buy
+531
New +$701K ﹤0.01% 4239
2020
Q3 		– Sell
-201
Closed -$234K – 5446
2020
Q2 		$234K Buy
+201
New +$182K ﹤0.01% 4731
2020
Q1 		– Sell
-352
Closed -$309K – 5398
2019
Q4 		$309K Buy
+352
New +$274K ﹤0.01% 4729

Other funds holding KRRO

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Goldman Sachs's KRRO Position: Q2 2026 in Review

Goldman Sachs increased its Korro Bio (KRRO) stake by 131% in Q2 2026, buying an estimated $826K and bringing the position to 116,983 shares worth $1.54M. The position accounts for ﹤0.01% of the portfolio, ranked #4879.

Goldman Sachs first reported a position in KRRO in Q4 2019 and has held it in 21 quarters since. The position peaked at $4.07M in Q1 2024. 107 funds tracked by Wall St. Rank hold KRRO as of Q2 2026.

  • Goldman Sachs held 116,983 shares of Korro Bio worth $1.54M as of Q2 2026.
  • Goldman Sachs bought 66,442 Korro Bio shares in Q2 2026, an estimated $826K.
  • Korro Bio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4879 holding.
  • Goldman Sachs first reported a position in Korro Bio in Q4 2019 and has held it in 21 quarters since.
  • Goldman Sachs's Korro Bio position peaked at $4.07M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Korro Bio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.